Sonnet BioTherapeutics Holdings, Inc. operates as a clinical stage biotechnology company. The Company develops fully human albumin binding technology that helps the development of innovative targeted biologic drugs with enhanced single-or bi-specific mechanisms. Sonnet BioTherapeutics Holdings serves customers in the United States.

Annual Report (Form 10-K | Period ending 2024-09-30)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Sonnet BioTherapeutics Holding (SONN US)

Annual Report (Form 10-K | Period ending 2024-09-30)

Current Report (Form 8-K | Period ending 2024-12-17)

Current Report (Form 8-K | Period ending 2024-12-09)

424B5 | Prospectus

Current Report (Form 8-K | Period ending 2024-12-09)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)